MedTrace Logo

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

NCT04946383 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-08-03

No results posted yet for this study

Summary

Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.

Conditions

  • Aging

Interventions

DRUG

Dasatinib plus Quercetin

Dasatinib plus Quercetin

Sponsors & Collaborators

  • TruDiagnostic

    lead INDUSTRY

Principal Investigators

  • Edwin Lee, MD · The Institute for Hormonal Balance

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-16
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04946383 on ClinicalTrials.gov